These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30702894)

  • 1. Proteomes of Paired Human Cerebrospinal Fluid and Plasma: Relation to Blood-Brain Barrier Permeability in Older Adults.
    Dayon L; Cominetti O; Wojcik J; Galindo AN; Oikonomidi A; Henry H; Migliavacca E; Kussmann M; Bowman GL; Popp J
    J Proteome Res; 2019 Mar; 18(3):1162-1174. PubMed ID: 30702894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults.
    Bowman GL; Dayon L; Kirkland R; Wojcik J; Peyratout G; Severin IC; Henry H; Oikonomidi A; Migliavacca E; Bacher M; Popp J
    Alzheimers Dement; 2018 Dec; 14(12):1640-1650. PubMed ID: 30120040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease.
    Wang H; Dey KK; Chen PC; Li Y; Niu M; Cho JH; Wang X; Bai B; Jiao Y; Chepyala SR; Haroutunian V; Zhang B; Beach TG; Peng J
    Mol Neurodegener; 2020 Jul; 15(1):43. PubMed ID: 32711556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-Brain Barrier Breakdown in Relationship to Alzheimer and Vascular Disease.
    Lin Z; Sur S; Liu P; Li Y; Jiang D; Hou X; Darrow J; Pillai JJ; Yasar S; Rosenberg P; Albert M; Moghekar A; Lu H
    Ann Neurol; 2021 Aug; 90(2):227-238. PubMed ID: 34041783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
    Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
    CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance.
    Bowman GL; Kaye JA; Moore M; Waichunas D; Carlson NE; Quinn JF
    Neurology; 2007 May; 68(21):1809-14. PubMed ID: 17515542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential disruption of blood-brain barrier in severe traumatic brain injury.
    Saw MM; Chamberlain J; Barr M; Morgan MP; Burnett JR; Ho KM
    Neurocrit Care; 2014 Apr; 20(2):209-16. PubMed ID: 24233818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease.
    Matsumoto Y; Yanase D; Noguchi-Shinohara M; Ono K; Yoshita M; Yamada M
    Dement Geriatr Cogn Disord; 2007; 23(4):241-5. PubMed ID: 17310121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
    Collins MA; An J; Hood BL; Conrads TP; Bowser RP
    J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyzing Cerebrospinal Fluid Proteomes to Characterize Central Nervous System Disorders: A Highly Automated Mass Spectrometry-Based Pipeline for Biomarker Discovery.
    Núñez Galindo A; Macron C; Cominetti O; Dayon L
    Methods Mol Biol; 2019; 1959():89-112. PubMed ID: 30852817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and cerebrospinal fluid inflammation and the blood-brain barrier in older surgical patients: the Role of Inflammation after Surgery for Elders (RISE) study.
    Vasunilashorn SM; Ngo LH; Dillon ST; Fong TG; Carlyle BC; Kivisäkk P; Trombetta BA; Vlassakov KV; Kunze LJ; Arnold SE; Xie Z; Inouye SK; Libermann TA; Marcantonio ER;
    J Neuroinflammation; 2021 Apr; 18(1):103. PubMed ID: 33931093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluid proteomics of CSF and serum reveal important neuroinflammatory proteins in blood-brain barrier disruption and outcome prediction following severe traumatic brain injury: a prospective, observational study.
    Lindblad C; Pin E; Just D; Al Nimer F; Nilsson P; Bellander BM; Svensson M; Piehl F; Thelin EP
    Crit Care; 2021 Mar; 25(1):103. PubMed ID: 33712077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood-brain barrier dysfunction.
    Mertens JC; Leenaerts D; Brouns R; Engelborghs S; Ieven M; De Deyn PP; Lambeir AM; Hendriks D
    J Thromb Haemost; 2018 Feb; 16(2):342-348. PubMed ID: 29194929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of APOE genotype with blood-brain barrier permeability in neurodegenerative disorders.
    Libri I; Silvestri C; Caratozzolo S; Alberici A; Pilotto A; Archetti S; Trainini L; Borroni B; Padovani A; Benussi A
    Neurobiol Aging; 2024 Aug; 140():33-40. PubMed ID: 38718740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Relationship between Markers of Inflammation and Degeneration in the Central Nervous System and the Blood-Brain Barrier Impairment in Alzheimer's Disease.
    Muszyński P; Kulczyńska-Przybik A; Borawska R; Litman-Zawadzka A; Słowik A; Klimkowicz-Mrowiec A; Pera J; Dziedzic T; Mroczko B
    J Alzheimers Dis; 2017; 59(3):903-912. PubMed ID: 28697565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimer's Disease Patients: A Report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL).
    Cardoso BR; Hare DJ; Bush AI; Li QX; Fowler CJ; Masters CL; Martins RN; Ganio K; Lothian A; Mukherjee S; Kapp EA; Roberts BR;
    J Alzheimers Dis; 2017; 57(1):183-193. PubMed ID: 28222503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aβ1-17 is a major amyloid-β fragment isoform in cerebrospinal fluid and blood with possible diagnostic value in Alzheimer's disease.
    Pérez-Grijalba V; Pesini P; Allué JA; Sarasa L; Montañés M; Lacosta AM; Casabona D; San-José I; Boada M; Tárraga L; Ruiz A; Sarasa M
    J Alzheimers Dis; 2015; 43(1):47-56. PubMed ID: 25061046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty.
    Ruan Q; D'Onofrio G; Sancarlo D; Greco A; Yu Z
    Mol Med Rep; 2016 Oct; 14(4):3184-98. PubMed ID: 27511317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The level of 24-Hydroxycholesteryl Esters is an Early Marker of Alzheimer's Disease.
    Benussi L; Ghidoni R; Dal Piaz F; Binetti G; Di Iorio G; Abrescia P
    J Alzheimers Dis; 2017; 56(2):825-833. PubMed ID: 27983556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.